Bellicum Pharmaceuticals, Inc. (BLCM) Financials

Stock symbol BLCM is outdated, potentially delisted? Maybe it is available on other exchange?

BLCM Assets vs Liabilities

Date	Assets	Liabilities
Sept. 30, 2023	6.9 million	33.9 million
June 30, 2023	8.7 million	30.6 million
March 31, 2023	17.3 million	27.3 million
Dec. 31, 2022	23.8 million	21.8 million

BLCM Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.

Date	Free Cash Flow	Stock based compensation
Sept. 30, 2023	-1.5 million	116000
June 30, 2023	-8.0 million	59000
March 31, 2023	-6.4 million	559000
Dec. 31, 2022	-6.9 million	714000

BLCM Net Income

No data available :(

BLCM Cash and Debt

Graph available only for paid members. Upgrade to see it.

Date	Cash	Debt	Capital Lease
Sept. 30, 2023	5.9 million	-	-
June 30, 2023	7.4 million	-	-
March 31, 2023	15.4 million	-	-
Dec. 31, 2022	21.8 million	-	-

BLCM Shares Outstanding

Graph available only for paid members. Upgrade to see it.

Date	Shares Outstanding
Sept. 30, 2023	30.9 million
June 30, 2023	30.8 million
March 31, 2023	30.8 million
Dec. 31, 2022	5.8 million

BLCM Expenses

Graph available only for paid members. Upgrade to see it.

Date	Capex	R&D	G&A	S&M
Sept. 30, 2023	-	263000	1.5 million	-
June 30, 2023	1000	4.8 million	2.3 million	-
March 31, 2023	5000	7.2 million	1.4 million	-
Dec. 31, 2022	7000	6.3 million	1.5 million	-

BLCM Cost of Revenue

Graph available only for paid members. Upgrade to see it.

Date	Revenue	Cost of Revenue
Sept. 30, 2023	1.0 million	-
June 30, 2023	-	-
March 31, 2023	8000	-
Dec. 31, 2022	500000	-

BLCM

Price: $0.07

52 week price:

0.06

1.43

Earnings Per Share: -0.72 USD

P/E Ratio: -0.13

Exchange: PNK

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 39500

Ebitda: -21.5 million

Market Capitalization: 778326

Links:

BLCM on Yahoo Finance